ESC Premium Access

Reasons and consequences of warfarin discontinuation in very elderly patients with non valvular atrial fibrillation. An inception cohort study.

Congress Presentation

About the speaker

Doctor Giacomo Zoppellaro

Hospital S.Giovanni e Paolo, Venezia (Italy)
0 follower

24 more presentations in this session

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

Speaker: Professor D. Xavier (Bangalore, IN)

Thumbnail

Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers

Speaker: Doctor C. Gatti (Ravenna, IT)

Thumbnail

High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

Speaker: Doctor D. Iglesias (Santiago de Compostela, ES)

Thumbnail

CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation

Speaker: Doctor J. Wieczorek (Katowice, PL)

Thumbnail

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Speaker: Doctor A. Parwani (Berlin, DE)

Thumbnail

Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation III

Speakers: Doctor G. Zoppellaro, Professor D. Xavier, Doctor C. Gatti, Doctor D. Iglesias, Doctor J. Wieczorek...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb